R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Research Associate - Drug Metabolism and Pharmacokinetics

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USAIn-person

About the Job

Requirements

  • A bachelor's or master's degree in pharmaceutical sciences or a related scientific discipline, with 5+ years of industry experience for bachelor's degree holders or 3+ years for master's degree holders.
  • Hands-on experience operating and maintaining LC-MS/MS systems.
  • Hands-on experience in LC-MS/MS method development and bioanalytical analysis.
  • Knowledge of biological sample preparation and extraction techniques for downstream LC-MS/MS analysis.
  • Hands-on experience in HPLC/UPLC method development.
  • Ability to customize and follow established assay protocols.
  • Ability to manage multiple laboratory and project tasks efficiently.
  • Ability to work effectively in a flexible, team-oriented environment.
  • Strong organization and attention to detail, with excellent recordkeeping and ability to adapt to a dynamic, fast-paced environment.

Responsibilities

  • Develop LC-MS/MS methods and analyze in vivo and in vitro samples to support ADME, pharmacokinetic, efficacy, and toxicokinetic studies.
  • Handle a variety of tissues, including tumors, from tissue homogenization through sample preparation for bioanalysis.
  • Perform data analysis, prepare experimental result reports, and upload data to electronic notebooks.
  • Conduct in vitro ADME/DMPK assays in biological matrices, including hepatocytes, microsomes, blood, and plasma.
  • Support laboratory operations, including lab safety, LC-MS/MS instrument maintenance, and troubleshooting.

Desired Qualifications

  • Previous hands-on experience with SCIEX QTRAP mass spectrometers.
  • Previous hands-on experience in bioanalytical method development in compliance with regulatory requirements.
  • Working experience in a DMPK laboratory.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs